Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
Apatinib
Refractory (planetary science)
DOI:
10.3892/ol.2021.12813
Publication Date:
2021-05-24T21:04:31Z
AUTHORS (12)
ABSTRACT
For osteosarcoma that progresses following first-line chemotherapy, prognosis remains poor although anti-angiogenesis tyrosine kinase inhibitors (TKIs) have been verified to prolong progression-free survival. Apatinib has led positive responses in the treatment of refractory osteosarcoma. However, it demonstrates only short-lived activity, and disease control rate musculoskeletal lesions is worse compared with pulmonary lesions. This failure partly overcome by addition ifosfamide etoposide (IE). The present study retrospectively activity apatinib + IE relapsed or two sarcoma centres China. included patients had received a combination 500 mg (orally) daily regimen (n=33) between June 3 2017 July 17 2020. tumour burden was considerable these patients: 16/33 (48.5%) Patients lung lesions, 31/33 (93.9%) progressed lines therapies at baseline. With median follow-up duration 28.4 [interquartile range (IQR), 16.1-38.3] months, 21/33 (63.6%) objective responses, event-free survival 11.4 (IQR, 6.7-18.4) months. overall time 19.8 13.1-30.6) At last follow-up, downstaging, all completely resected. multiple sites metastasis, demonstrated clinically meaningful antitumor delayed progression recurrent after chemotherapy. manageable toxicity deserves further investigation prospective trials.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (11)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....